Team members for the Curevc
Dr. Weihan Liu is an Associate at Cure Ventures, with over ten years of experience in biomedical research. Most recently, Weihan was a consultant at ClearView Healthcare Partners, where he worked with pharma and biotech companies to address critical challenges in drug development and commercialization. Prior to that, he earned his Ph.D. at the University […]
Dr. MacIsaac is a Partner at Cure Ventures. Kenzie’s career spans over 13 years in drug discovery working at the cutting edge of genetics, genomics, and bioinformatics to solve pressing problems in human health. Prior to joining Cure Ventures, Dr. MacIsaac served as a Senior Director at Bristol Myers Squibb where he built out the
Kenzie Maclsaac, Ph.D. Read More »
Annie is an experienced investment professional with over ten years of academic licensing and venture investing experience. Prior to joining Cure, Annie was an independent consultant to several VC-backed biotech companies, within oncology, gene therapy and RNA therapeutics. Annie spent over six years on the investment team at Omega Funds, where she sourced, diligenced and
Annie Mitsak, Ph.D. Read More »
Dr. Robichaud (Al) is a Partner of Cure Ventures with over three decades of industry experience focused primarily on neuroscience. Prior to joining Cure, he was the founding scientist and Chief Scientific Officer at Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare CNS disorders. While there, Al helped launch the
Albert J. Robichaud, Ph.D. Read More »
Dr. Robinson (Sophie) is an Associate at Cure Ventures with over a decade of experience in academic research and industry, both in the United States and abroad. Prior to joining Cure Ventures, Sophie was a doctoral candidate at the German Center of Neurodegenerative Diseases and the Institute for Stroke and Dementia Research in Munich, Germany.
Sophie Robinson, Ph.D. Read More »
Ms. Szottfried (Kim) is an Executive Assistant at Cure Ventures with over 30 years of experience in accounting, operations, and administrative roles. Supporting the entire team, Kim is responsible for calendar and meeting management, event planning, and project coordination at the firm. Prior to joining Cure Ventures, Kim was a Finance Associate at Easterly Partners
Dr. Tartaglia (Lou) is a Managing Partner and Co-Founder of Cure Ventures. Lou’s career spans more than 30 years demonstrating scientific and therapeutic product project leadership within the biotech industry as well as investment leadership within multiple venture capital firms. His experience and skills as a rigorous scientist have manifested itself across a wide array
Lou Tartaglia, Ph.D. Read More »
